BioVie Secures $12.6 Million Grant for Phase 2 Trial of Bezisterim Targeting Long COVID

Monday, 16 September 2024, 02:47

BioVie Inc. has received a $12.6 million grant to advance its Phase 2 trial of Bezisterim for long COVID. This funding comes from the U.S. Department of Defense, underscoring the importance of addressing long-term symptoms that some experience after COVID-19. The trial aims to investigate potential treatments for these persistent health issues. This initiative represents a significant step in the response to long COVID.
LivaRava_Health_Default_2.png
BioVie Secures $12.6 Million Grant for Phase 2 Trial of Bezisterim Targeting Long COVID

Understanding the Importance of Bezisterim in Long COVID Treatment

BioVie Inc. has announced a remarkable achievement with the approval of a $12.6 million grant from the U.S. Department of Defense. This funding is aimed at initiating a Phase 2 trial for its innovative drug, Bezisterim, specifically targeting long COVID symptoms.

The Significance of the Trial

  • This trial marks a vital step in addressing the long-term health complications associated with COVID-19.
  • Bezisterim's potential efficacy could lead to better management of persistent symptoms.
  • The grant showcases support for medical research focusing on health after viral infections.

As the healthcare industry continues to recognize the implications of long COVID, studies like this are crucial for developing effective treatment strategies.


Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest and most reliable health updates. Stay informed and enhance your wellness knowledge effortlessly.

Subscribe